Yang, Y., Jain, R. K., Gupta, S., Tsung, I., Gopalakrishnan, D., Gheeya, J. S., Wei, L., Satturwar, S., Parwani, A., Collier, K. A., Pohar, K. S., Sundi, D., Lee, C. T., Li, Z., Roychowdhury, S., Mortazavi, A. (2025). A phase 2 trial of neoadjuvant futibatinib plus durvalumab for cisplatin-ineligible patients with FGFR overexpressing muscle-invasive bladder cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.tps899